In March 2026, Sanofi announced that its drug rilzabrutinib received orphan drug designation in Japan for IgG4-related disease on March 2, revealed an amendment to its Annual Financial Report on March 4, and proposed the appointment of Christel Heydemann as an independent director on March 5.